Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: sublime45 who wrote (59175)	12/30/2020 1:33:49 PM
From: allatwwk	5 Recommendations Recommended By bnutman dorightbythem erippetoe Farmland idahoranch1 Read Replies (1) \| Respond to of 63276

Decided to buy some GILD. Will buy more if the price drops another 10% of so. Have to believe some of the recent price issue has been tax loss selling. That ends and the reason to sell lightens up. GILD mgmt has been on a buying spree in recent times. IMMU was the biggest, but not the only significant spend. I'd like to see them start to dispose of some non-core assets or exit certain businesses. The CEO is transforming GILD into something different than its been, but its not clear what. Whether this succeeds or not, hard to say. But this seems to be a case where an "unlocking value" story exists -- where the same asset under a different corporate nameplate is probably worth more than under the GILD nameplate. In other words, there's downside protection. Lastly, I've mentioned my biopharma basket -- a series of small biopharmas which add up to 1 normal position. Here's how its done in 2020. Down: CBAY Flat to up 20%: HTRX, MRNS, FENC Up 20% to 50%: MRSN, CERS, RPRX Up > 50%: SDGR Donated my MRNA shares, which was best performer (bought before pandemic, fwiw). Put in place a "sell 30% of shares if gain goes over 50%" to make sure I can lock in some profits if a stock surges. Only SDGR hit that mark. Among larger pharma, also hold MRK and now GILD. Combined, all these positions are under 10% of what I had in IMMU (after taxes). I'm happy to ride pharma kiddie roller coaster from now on. I know 2020 has been a difficult year for many, even with the IMMU win. So here's hoping for a prosperous 2021 -- and more importantly, a healthy 2021 to all.